HU230189B1 - Szerotonin újrafelvételt gátló fenilpiperazin-származékok - Google Patents

Szerotonin újrafelvételt gátló fenilpiperazin-származékok Download PDF

Info

Publication number
HU230189B1
HU230189B1 HU1300028A HUP1300028A HU230189B1 HU 230189 B1 HU230189 B1 HU 230189B1 HU 1300028 A HU1300028 A HU 1300028A HU P1300028 A HUP1300028 A HU P1300028A HU 230189 B1 HU230189 B1 HU 230189B1
Authority
HU
Hungary
Prior art keywords
alkyl
carbon atoms
group
carbon
alkenyl
Prior art date
Application number
HU1300028A
Other languages
English (en)
Hungarian (hu)
Inventor
Thomas Ruhland
Garrick Paul Smith
Benny Bang-Andersen
Ask Püschl
Ejner Knud Moltzen
Kim Andersen
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8160750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HU230189(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of HU230189B1 publication Critical patent/HU230189B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HU1300028A 2001-10-04 2002-10-02 Szerotonin újrafelvételt gátló fenilpiperazin-származékok HU230189B1 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200101466 2001-10-04
DKPA200101466 2001-10-04
PCT/DK2002/000659 WO2003029232A1 (en) 2001-10-04 2002-10-02 Phenyl-piperazine derivatives as serotonin reuptake inhibitors

Publications (1)

Publication Number Publication Date
HU230189B1 true HU230189B1 (hu) 2015-09-28

Family

ID=8160750

Family Applications (3)

Application Number Title Priority Date Filing Date
HU1300028A HU230189B1 (hu) 2001-10-04 2002-10-02 Szerotonin újrafelvételt gátló fenilpiperazin-származékok
HU0402313A HU228956B1 (en) 2001-10-04 2002-10-02 Phenyl-piperazine derivatives as serotonin reuptake inhibitors
HUS1400012C HUS1400012I1 (hu) 2001-10-04 2014-03-12 Szerotonin újrafelvételt gátló fenilpiperazin-származékok

Family Applications After (2)

Application Number Title Priority Date Filing Date
HU0402313A HU228956B1 (en) 2001-10-04 2002-10-02 Phenyl-piperazine derivatives as serotonin reuptake inhibitors
HUS1400012C HUS1400012I1 (hu) 2001-10-04 2014-03-12 Szerotonin újrafelvételt gátló fenilpiperazin-származékok

Country Status (38)

Country Link
US (10) US7144884B2 (cg-RX-API-DMAC10.html)
EP (2) EP1749818B1 (cg-RX-API-DMAC10.html)
JP (3) JP3896116B2 (cg-RX-API-DMAC10.html)
KR (3) KR100783346B1 (cg-RX-API-DMAC10.html)
CN (1) CN1319958C (cg-RX-API-DMAC10.html)
AR (2) AR036659A1 (cg-RX-API-DMAC10.html)
AT (2) ATE441631T1 (cg-RX-API-DMAC10.html)
AU (2) AU2002333220C1 (cg-RX-API-DMAC10.html)
BE (1) BE2014C036I2 (cg-RX-API-DMAC10.html)
BR (3) BR122012009534C8 (cg-RX-API-DMAC10.html)
CA (1) CA2462110C (cg-RX-API-DMAC10.html)
CO (1) CO5580746A2 (cg-RX-API-DMAC10.html)
CY (3) CY1107924T1 (cg-RX-API-DMAC10.html)
DE (2) DE60225162T3 (cg-RX-API-DMAC10.html)
DK (2) DK1749818T3 (cg-RX-API-DMAC10.html)
EA (2) EA011096B1 (cg-RX-API-DMAC10.html)
EG (1) EG25095A (cg-RX-API-DMAC10.html)
ES (2) ES2328725T3 (cg-RX-API-DMAC10.html)
FR (1) FR14C0033I2 (cg-RX-API-DMAC10.html)
HR (1) HRP20040220A2 (cg-RX-API-DMAC10.html)
HU (3) HU230189B1 (cg-RX-API-DMAC10.html)
IL (1) IL160655A0 (cg-RX-API-DMAC10.html)
IS (2) IS2578B (cg-RX-API-DMAC10.html)
LT (1) LTC1436271I2 (cg-RX-API-DMAC10.html)
LU (1) LU92397I2 (cg-RX-API-DMAC10.html)
ME (1) ME00039B (cg-RX-API-DMAC10.html)
MX (1) MXPA04002959A (cg-RX-API-DMAC10.html)
MY (1) MY140950A (cg-RX-API-DMAC10.html)
NL (1) NL300652I1 (cg-RX-API-DMAC10.html)
NO (3) NO326443B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ531556A (cg-RX-API-DMAC10.html)
PL (2) PL209253B1 (cg-RX-API-DMAC10.html)
PT (2) PT1436271E (cg-RX-API-DMAC10.html)
RS (2) RS52326B (cg-RX-API-DMAC10.html)
SI (1) SI1436271T1 (cg-RX-API-DMAC10.html)
UA (2) UA81749C2 (cg-RX-API-DMAC10.html)
WO (1) WO2003029232A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200401583B (cg-RX-API-DMAC10.html)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
GB0305575D0 (en) * 2003-03-11 2003-04-16 Glaxo Group Ltd Novel compounds
NZ540891A (en) * 2003-04-04 2008-07-31 Lundbeck & Co As H 4-(2-Phenyloxyphenyl)-piperidine or -1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors
CL2004000726A1 (es) * 2003-04-04 2005-05-20 Lundbeck & Co As H Compuestos derivados de 4-[2-(feniloxi sustituido)fenil]piperidina o -1,2,3,6-tetrahidropiridina; composcion farmaceutica que los contiene; y su uso para el tratamiento de trastornos afectivos, tales como la depresion, trastornos de ansiedad, de ansi
KR101107536B1 (ko) * 2003-04-04 2012-01-31 하. 룬트벡 아크티에 셀스카브 세로토닌 재흡수 저해제로서의4-(2-페닐술파닐-페닐)-피페리딘 유도체
UA81300C2 (en) * 2003-04-04 2007-12-25 Lundbeck & Co As H Derivates of 4-(2-fenilsulfanilfenil)-1,2,3,6-tetrahydropiridin as retarding agents of serotonin recapture
DK1626720T3 (da) * 2003-04-04 2008-12-01 Lundbeck & Co As H 4-(2-Phenylsulfanyl-phenyl)-piperidinderivater som serotonin-genoptagelseshæmmer
PT1701940E (pt) 2003-12-23 2008-07-30 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-benzil-amina como ssri
AR052308A1 (es) * 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
DE602006007550D1 (de) * 2005-02-10 2009-08-13 Neurosearch As Alkylsubstituierte homopiperazinderivate und deren verwendung als monoamin neurotransmitter wiederaufnahmeinhibitoren
AR054394A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de 2- (1h-indolilsulfanil)-aril amina
AR054393A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.
US7629473B2 (en) 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
JP2007106746A (ja) * 2005-09-13 2007-04-26 Tosoh Corp 新規アリールホモピペラジン類、またはその塩と製造方法
ATE540941T1 (de) 2006-06-16 2012-01-15 Lundbeck & Co As H 1-ä2-(2,4-dimethylphenylsulfanyl)phenylüpiperaz n als verbindung mit kombinierter serotoninwiederaufnahme-, 5-ht3- und 5-ht1a- aktivität zur behandlung kognitiver störungen
CA2656057C (en) * 2006-06-16 2012-10-02 H. Lundbeck A/S Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
DE602007014372D1 (de) * 2006-06-16 2011-06-16 Lundbeck & Co As H Kristalline formen von 4-ä2-(4-methylphenylsulfany norepinephrinwiederaufnahmehemmung zur behandlung neuropathischer schmerzen
ZA200809917B (en) * 2006-06-16 2010-08-25 Lundbeck & Co As H Crystalline forms of 4- [2-(4-Methylphenylsulfanyl) - Phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
JP7179035B2 (ja) * 2006-06-16 2022-11-28 ハー・ルンドベック・アクチエゼルスカベット 認識機能障害（ｃｏｇｎｉｔｉｖｅ ｉｍｐａｉｒｍｅｎｔ）を治療するための、組み合わされたセロトニン再取り込み、５－ＨＴ３および５－ＨＴ１Ａ活性を有する化合物としての１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン
TW200848411A (en) 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TWI432194B (zh) * 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
TWI405588B (zh) * 2007-03-20 2013-08-21 Lundbeck & Co As H ４-〔２-（４-甲苯基硫基）-苯基〕哌啶之鹽類的液體調配物
HRP20140044T1 (hr) * 2007-06-15 2014-02-14 H. Lundbeck A/S 4-[2-(4-metilfenilsulfanil)fenil]piperidin za lijeäśenje iritabilnog sindroma crijeva (ibs)
TW200932233A (en) 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
AU2014200364B2 (en) * 2007-11-13 2015-09-17 H. Lundbeck A/S Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity
TW200932225A (en) * 2007-12-14 2009-08-01 Lundbeck & Co As H 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine
TW200938194A (en) * 2007-12-14 2009-09-16 Lundbeck & Co As H Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter
WO2009081259A1 (en) * 2007-12-21 2009-07-02 Pfizer Inc. Phenoxy-pyridyl derivatives
UA98698C2 (en) * 2008-03-03 2012-06-11 Х. Луннбек А/С Phenylsulfanylphenyl-piperidines and process for the preparation thereof
EP2358675B9 (en) 2008-11-14 2019-09-11 Theravance, Inc. 4-[2-(2-Fluorophenoxymethyl)phenyl]piperidine compounds
TW201033181A (en) * 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
SI2421534T1 (sl) * 2009-04-24 2014-11-28 H. Lundbeck A/S Tekoče formulacije soli 1-(2-(2,4-dimetilfenilsulfanil) fenil) piperazina
BR112012003280A2 (pt) 2009-08-24 2017-05-23 H Lundbeck As composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto.
EP2493852B1 (en) * 2009-10-30 2014-04-09 Janssen Pharmaceutica NV 4-substituted-2-phenoxy-phenylamine delta opioid receptor modulators
EP2523945A1 (en) 2010-01-11 2012-11-21 Theravance, Inc. 1 - (2 - phenoxymethylphenyl) piperazine compounds as serotonin and norepinephrine reuptake inhibitors
WO2011119461A1 (en) * 2010-03-22 2011-09-29 Theravance, Inc. 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds
WO2011136376A1 (ja) * 2010-04-30 2011-11-03 武田薬品工業株式会社 腸溶性錠剤
GEP20166487B (en) * 2010-04-30 2016-06-10 Takeda Pharmaceutical Enteric tablet
EP2407467A1 (de) 2010-07-14 2012-01-18 Sandoz Ag Kristalline Verbindung von 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol und Milchsäure
TW201212918A (en) 2010-08-23 2012-04-01 Lundbeck & Co As H Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
SMT201900179T1 (it) 2011-06-20 2019-05-10 H Lundbeck As 1–piperazino–3–fenil indani deuterati per il trattamento della schizofrenia
AU2012340015B2 (en) 2011-11-14 2017-09-21 Alfasigma S.P.A. Assays for selecting a treatment regimen for a subject with depression and methods for treatment
WO2013102573A1 (en) * 2012-01-03 2013-07-11 H. Lundbeck A/S Process for the manufacture of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine
BR112015006075B1 (pt) 2012-09-19 2022-10-04 Sandoz Ag Composto cristalino, composição farmacêutica, uso do composto cristalino, hidrato cristalino do bromidrato de vortioxetina, método para a preparação do hidrato cristalino de bromidrato de vortioxetina, método para a preparação do composto cristalino e uso do hidrato cristalino de bromidrato de vortioxetina
WO2014090929A1 (en) 2012-12-13 2014-06-19 H. Lundbeck A/S Compositions comprising vortioxetine and donepezil
UA116236C2 (uk) * 2013-02-22 2018-02-26 Х. Луннбек А/С Спосіб одержання вортіоксетину
PL2981520T3 (pl) * 2013-04-04 2019-09-30 Lek Pharmaceuticals D.D. Nowy sposób syntezy 1-(2-((2,4-dimetylofenylo)tio)fenylo)piperazyny
CN104109135B (zh) * 2013-04-22 2018-10-26 江苏豪森药业集团有限公司 1-[2-(2,4-二甲基苯基硫烷基)-苯基]哌嗪的制备方法
IN2013MU03121A (cg-RX-API-DMAC10.html) 2013-09-30 2015-07-17 Cadila Healthcare Ltd
EP2878596A1 (en) * 2013-11-29 2015-06-03 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates
CN104710345B (zh) * 2013-12-17 2017-09-05 江苏恩华药业股份有限公司 用于制备4‑（2‑（4‑甲基苯基硫基））苯基哌啶的化合物、其制备方法及应用
CA2933733A1 (en) 2013-12-20 2015-06-25 Connie Sanchez Morillo Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
EP2894154A1 (en) 2014-01-14 2015-07-15 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)aniline intermediates
CN103788019B (zh) * 2014-01-22 2015-10-07 苏州明锐医药科技有限公司 沃替西汀的制备方法
EP3099669A1 (en) 2014-01-31 2016-12-07 Egis Gyógyszergyár Zrt. Process for the preparation of vortioxetine salts
EP2930171A1 (en) 2014-04-07 2015-10-14 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2,4-dimethylphenyl)(2-iodophenyl)sulfane intermediate
CN104059030B (zh) * 2014-05-30 2016-05-04 镇江圣安医药有限公司 [(苯硫烷基)-苯基]哌嗪的衍生物及其药物组合物和用途
FR3023320B1 (fr) * 2014-07-03 2017-03-10 Ifp Energies Now Systeme et procede de stockage et de recuperation d'energie par gaz comprime avec stockage de la chaleur au moyen d'un echangeur radial
CZ2014471A3 (cs) 2014-07-08 2016-01-20 Zentiva, K.S. Způsob přípravy vortioxetinu
US9687484B2 (en) 2014-07-18 2017-06-27 Dipharma Francis S.R.L. Crystalline forms of an antidepressant compound
CN104146953A (zh) * 2014-07-24 2014-11-19 李雪梅 一种氢溴酸沃替西汀注射液
CN104292183B (zh) * 2014-09-29 2016-01-06 杨献美 一种抗抑郁药物沃替西汀的制备方法
WO2016079751A2 (en) 2014-11-17 2016-05-26 Megafine Pharma (P) Ltd. A process for preparation of vortioxetine and polymorphs thereof
ES2634496T3 (es) 2014-11-21 2017-09-28 Dipharma Francis S.R.L. Proceso para la preparación de un antidepresivo y los intermedios del mismo
CN104447622B (zh) * 2014-11-28 2017-01-04 郑州大明药物科技有限公司 氢溴酸沃替西汀β晶型的制备方法
CN104586756A (zh) * 2015-01-05 2015-05-06 万特制药(海南)有限公司 一种含沃替西汀的口服溶液及其制备方法
CZ201531A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Polymerem stabilizované amorfní formy vortioxetinu
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
WO2016125190A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof
WO2016125191A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Processes for the preparation of vortioxetine hydrobromide
US10227317B2 (en) 2015-02-25 2019-03-12 Lupin Limited Process for the preparation of vortioxetine
EP3274330A1 (en) 2015-03-26 2018-01-31 Cipla Limited Method for making serotonin reuptake inhibitors
CN104829557B (zh) * 2015-04-23 2017-06-27 山东百诺医药股份有限公司 一种新化合物1‑[2‑（2,4‑二甲基苯基硫基）苯基]‑2‑氧哌嗪及其制备方法和在沃替西汀合成中的应用
JO3456B1 (ar) 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
WO2017013031A1 (en) * 2015-07-17 2017-01-26 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation
EP3337789A1 (en) * 2015-08-19 2018-06-27 Amneal Pharmaceuticals Company GmbH Process for preparation of vortioxetine hydrobromide
US20180303772A1 (en) * 2015-10-14 2018-10-25 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for the treatment of myocardial infarction
CN105461635B (zh) * 2015-11-18 2018-06-08 乳源瑶族自治县大众药品贸易有限公司 苯基哌嗪衍生物及其使用方法和用途
CN105348204B (zh) * 2015-11-18 2018-09-14 乳源瑶族自治县大众药品贸易有限公司 1-杂环基-2-(杂芳基硫基)苯衍生物及其使用方法和用途
US11013830B2 (en) 2015-11-20 2021-05-25 Institut Pasteur 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
WO2017162536A1 (en) 2016-03-21 2017-09-28 H. Lundbeck A/S Vortioxetine prodrugs
TW201806599A (zh) 2016-07-01 2018-03-01 Ｈ 朗德貝克公司 用於快速開始抗抑鬱作用之給藥方案
EP3484462B1 (en) 2016-07-15 2022-12-14 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for skin and/or hair repair
KR20190032418A (ko) * 2016-07-22 2019-03-27 지앙수 인화뤄캉 파마슈티컬 리서치 앤드 디벨롭먼트 컴퍼니 리미티드 보티옥세틴 유사체와 용도 및 이의 제조
WO2018042168A1 (en) 2016-08-29 2018-03-08 King, Lawrence Stable pharmaceutical composition of vortioxetine hydrobromide
CN106349132B (zh) * 2016-08-30 2018-02-02 重庆植恩药业有限公司 沃替西汀中间体杂质及其制备方法和用途
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
CN108409728B (zh) * 2017-02-09 2020-11-24 广东东阳光药业有限公司 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途
CN108409729B (zh) * 2017-02-09 2020-11-24 广东东阳光药业有限公司 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途
US10428033B2 (en) 2017-02-15 2019-10-01 Piramal Enterprises Limited Process for the preparation of vortioxetine and salts thereof
WO2018150344A1 (en) 2017-02-17 2018-08-23 Unichem Laboratories Ltd Bioequivalent pharmaceutical composition of vortioxetine hydrobromide
US10836730B2 (en) 2017-02-23 2020-11-17 Unichem Laboratories Ltd. Process for preparation and purification of vortioxetine hydrobromide
SMT202200073T1 (it) 2017-04-25 2022-03-21 H Lundbeck As Processo per la produzione di vortioxeti-na hbr di forma alfa
EP3412661A1 (en) 2017-06-08 2018-12-12 Enantia, S.L. Cocrystals of vortioxetine hydrobromide and resorcinol
KR102026337B1 (ko) 2017-07-07 2019-09-27 영진약품 주식회사 1-[2-(2,4-디메틸페닐설파닐)페닐]피페라진의 신규염 및 이의 제조방법
CN107915685A (zh) * 2017-12-11 2018-04-17 重庆植恩药业有限公司 一种氢溴酸沃替西汀中间体的制备方法
CN108017595A (zh) * 2017-12-20 2018-05-11 安徽源久源科技有限公司 一种1-[2-(2,5-二甲基苯硫基)苯基]哌嗪的制备方法
PL3810582T3 (pl) 2018-06-20 2024-05-13 Vio Ag Pharmaceuticals S.A. Jednonaczyniowy sposób organopseudokatalitycznej aktywacji c-h do wytwarzania wortioksetyny i związku pośredniego wortioksetyny
CN108863986B (zh) * 2018-08-06 2020-01-21 广东东阳光药业有限公司 二氟甲基取代的苯基哌嗪衍生物及其用途
CN108727393B (zh) * 2018-08-06 2019-10-29 广东东阳光药业有限公司 苯基二氮杂双环衍生物及其用途
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
WO2021198778A1 (en) 2020-04-03 2021-10-07 H. Lundbeck A/S 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine for prevention or treatment of emotional blunting
WO2022052391A1 (zh) 2020-09-10 2022-03-17 苏州富德兆丰生化科技有限公司 伏硫西汀的合成方法
GB2622880A (en) 2022-09-30 2024-04-03 Alkaloid Ad Skopje Palatable orodispersible formulation of vortioxetine
WO2025132869A1 (en) 2023-12-21 2025-06-26 H. Lundbeck A/S Method for the preparation of vortioxetine pharmaceutical compositions with low amounts of nitrosamine impurities
CN120774863A (zh) * 2024-04-02 2025-10-14 王春刚 一种烷基二胺取代双芳杂环基硫醚类化合物及其制备和在制备治疗和/或预防肿瘤药物中的应用
EP4681702A1 (en) 2024-07-16 2026-01-21 PharmaPath S.A. Oral solution comprising vortioxetine hydrobromide

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS151752B1 (cg-RX-API-DMAC10.html) 1971-04-13 1973-11-19
CS151753B1 (cg-RX-API-DMAC10.html) 1971-04-13 1973-11-19
CS151755B1 (cg-RX-API-DMAC10.html) 1971-04-13 1973-11-19
CS151751B1 (cg-RX-API-DMAC10.html) 1971-04-13 1973-11-19
YU163075A (en) 1975-07-21 1982-05-31 Science Union & Cie Process for preparing new phenoxy derivatives
US4241071A (en) 1977-01-27 1980-12-23 American Hoechst Corporation Antidepressant (α-phenyl-2-tolyl)azacycloalkanes
US4198417A (en) 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
US4198419A (en) 1979-01-10 1980-04-15 American Hoechst Corporation Phenylthiophenylpiperidines
ES2004809A6 (es) 1987-07-29 1989-02-01 Ferrer Int Procedimiento de obtencion de nuevas 1-(2-(fenilmetil)fenil)piperazinas
GB9126311D0 (en) 1991-12-11 1992-02-12 Wellcome Found Substituted diphenylsulfides
US6048876A (en) 1995-01-23 2000-04-11 Suntory Limited Medicament for the alleviation or treatment of symptom derived from ischemic disease and compound useful therefor
CZ293595A3 (cs) 1995-11-09 1999-12-15 Farmak A. S. Deriváty N,N-dimethyl-2-(arylthio)benzylaminu, jejich soli, způsoby jejich přípravy a jejich použití v léčivých přípravcích
FR2757160B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa 1-phenylalkyl-1,2,3,6-tetrahydropyridines
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
ES2230209T3 (es) * 1997-10-31 2005-05-01 Daiichi Suntory Pharma Co., Ltd. Procedimiento para preparar n-((4-fenil)metilfenil)piperazinas.
IL145528A0 (en) 1999-04-02 2002-06-30 Icos Corp INHIBITORS OF LFA-1 BINDING TO ICAMs AND USES THEREOF
BR0012984A (pt) 1999-08-04 2002-07-16 Millennium Pharm Inc Método para tratar um estado associado com o mc4-r em um mamìfero, composto de ligação ao mc4-r, e, composição farmacêutica
CA2384599A1 (en) * 1999-09-14 2001-03-22 Pharmacopeia, Inc. Article comprising a multi-channel dispensing head
AU2351701A (en) * 1999-12-30 2001-07-16 H. Lundbeck A/S A method for the preparation of substituted benzene derivatives
CA2395705C (en) * 1999-12-30 2006-10-17 H. Lundbeck A/S Substituted phenyl-piperazine derivatives, their preparation and use
US6813639B2 (en) 2000-01-26 2004-11-02 Viaclix, Inc. Method for establishing channel-based internet access network
DE10033548C2 (de) 2000-07-11 2002-05-16 Wolfgang Papenbrock Verfahren zur Vorschau von Internetseiten
ES2246390T3 (es) * 2001-01-23 2006-02-16 Eli Lilly And Company Derivados de piperazina como agonistas del receptor de melanocortina.
WO2002062766A2 (en) 2001-02-07 2002-08-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
AU2002351734A1 (en) * 2001-12-20 2003-07-09 H. Lundbeck A/S Aryloxyphenlyl and arylsulfanylphenyl derivatives
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
DK1626720T3 (da) * 2003-04-04 2008-12-01 Lundbeck & Co As H 4-(2-Phenylsulfanyl-phenyl)-piperidinderivater som serotonin-genoptagelseshæmmer
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
ATE540941T1 (de) * 2006-06-16 2012-01-15 Lundbeck & Co As H 1-ä2-(2,4-dimethylphenylsulfanyl)phenylüpiperaz n als verbindung mit kombinierter serotoninwiederaufnahme-, 5-ht3- und 5-ht1a- aktivität zur behandlung kognitiver störungen

Also Published As

Publication number Publication date
BR122012023120B8 (pt) 2022-01-18
ES2298425T7 (es) 2022-06-27
KR20060118020A (ko) 2006-11-17
BR122012009534B1 (pt) 2018-02-27
PL210551B1 (pl) 2012-02-29
JP3955613B2 (ja) 2007-08-08
EP1749818B1 (en) 2009-09-02
US20050014740A1 (en) 2005-01-20
CO5580746A2 (es) 2005-11-30
IS2732B (is) 2011-04-15
CA2462110C (en) 2010-05-11
PT1749818E (pt) 2009-10-06
CY2014022I1 (el) 2015-12-09
BE2014C036I2 (cg-RX-API-DMAC10.html) 2021-11-22
US20110009423A1 (en) 2011-01-13
AU2006215994B2 (en) 2008-11-13
BR122012009534B8 (pt) 2019-01-29
LTC1436271I2 (lt) 2016-09-12
NO326443B1 (no) 2008-12-08
KR100783346B1 (ko) 2007-12-07
EP1436271A1 (en) 2004-07-14
EA200400498A1 (ru) 2004-08-26
PT1436271E (pt) 2008-04-10
JP2007051149A (ja) 2007-03-01
UA81749C2 (uk) 2008-02-11
HUP0402313A2 (hu) 2005-02-28
HUS1400012I1 (hu) 2020-12-28
DE60225162D1 (de) 2008-04-03
MXPA04002959A (es) 2004-07-05
IS8806A (is) 2009-03-10
BRPI0212733B8 (pt) 2021-05-25
EA011096B1 (ru) 2008-12-30
NL300652I2 (cg-RX-API-DMAC10.html) 2016-01-18
US7138407B2 (en) 2006-11-21
WO2003029232A1 (en) 2003-04-10
PL368442A1 (pl) 2005-03-21
US7683053B2 (en) 2010-03-23
US8476279B2 (en) 2013-07-02
DE60233608D1 (de) 2009-10-15
EA007537B1 (ru) 2006-10-27
HUP0402313A3 (en) 2010-03-29
KR20070103515A (ko) 2007-10-23
PL209253B1 (pl) 2011-08-31
EP1436271B1 (en) 2008-02-20
US20120302553A1 (en) 2012-11-29
KR100770194B1 (ko) 2007-10-25
RS52865B (sr) 2013-12-31
SI1436271T1 (sl) 2008-06-30
CY2014022I2 (el) 2015-12-09
FR14C0033I2 (fr) 2014-11-14
BR122012023120B1 (pt) 2017-03-21
US20060084662A1 (en) 2006-04-20
BR122012009534C8 (pt) 2021-05-25
DE60225162T3 (de) 2022-08-11
DK1436271T3 (da) 2008-06-09
US7148238B2 (en) 2006-12-12
CA2462110A1 (en) 2003-04-10
LU92397I2 (fr) 2014-05-12
NO20083446L (no) 2004-04-21
ME00039B (me) 2010-06-10
AU2002333220C1 (en) 2023-10-05
KR20040047886A (ko) 2004-06-05
AU2002333220B2 (en) 2008-02-07
MEP6508A (xx) 2010-02-10
CN1319958C (zh) 2007-06-06
NZ531556A (en) 2005-12-23
RS52326B (sr) 2012-12-31
JP2007031447A (ja) 2007-02-08
US20180127389A1 (en) 2018-05-10
HU228956B1 (en) 2013-07-29
ZA200401583B (en) 2005-05-25
CA2462110E (en) 2003-04-10
NO2014011I2 (no) 2015-08-31
ATE386730T1 (de) 2008-03-15
NL300652I1 (cg-RX-API-DMAC10.html) 2016-01-18
LTPA2014013I1 (lt) 2014-04-25
US20160137620A1 (en) 2016-05-19
BR0212733B1 (pt) 2014-05-13
US9090575B2 (en) 2015-07-28
DK1436271T6 (da) 2022-06-27
EP1749818A3 (en) 2008-04-02
RS27704A (sr) 2006-10-27
AR066460A2 (es) 2009-08-19
US9708280B2 (en) 2017-07-18
FR14C0033I1 (cg-RX-API-DMAC10.html) 2014-06-13
AU2006215994A9 (en) 2006-10-05
US20060089368A1 (en) 2006-04-27
NO20041628L (no) 2004-04-21
AU2006215994A1 (en) 2006-10-05
BR0212733A (pt) 2004-11-16
IL160655A0 (en) 2004-07-25
MY140950A (en) 2010-02-12
AU2006215994A2 (en) 2006-10-05
RS20120158A2 (sr) 2012-10-31
ES2328725T3 (es) 2009-11-17
EA200601269A1 (ru) 2007-02-27
JP3896116B2 (ja) 2007-03-22
CN1561336A (zh) 2005-01-05
DK1749818T3 (da) 2009-10-12
US8110567B2 (en) 2012-02-07
IS2578B (is) 2010-02-15
EP1749818A2 (en) 2007-02-07
US20070060574A1 (en) 2007-03-15
US20210276966A1 (en) 2021-09-09
US20140163043A1 (en) 2014-06-12
CY1110064T1 (el) 2015-01-14
ES2298425T3 (es) 2008-05-16
NO2014011I1 (no) 2014-05-13
HK1072600A1 (zh) 2005-09-02
RS20120158A3 (en) 2013-10-31
US10844029B2 (en) 2020-11-24
ATE441631T1 (de) 2009-09-15
KR100842702B1 (ko) 2008-07-01
HRP20040220A2 (en) 2005-02-28
EG25095A (en) 2011-08-17
EA007537B3 (ru) 2015-02-27
AR036659A1 (es) 2004-09-22
JP2005505585A (ja) 2005-02-24
JP3955614B2 (ja) 2007-08-08
US7144884B2 (en) 2006-12-05
NO332355B1 (no) 2012-09-03
UA93857C2 (uk) 2011-03-25
CY1107924T1 (el) 2013-09-04
EP1436271B3 (en) 2022-04-20
IS7164A (is) 2004-02-26
AU2002333220A2 (en) 2003-04-14
DE60225162T2 (de) 2009-02-12

Similar Documents

Publication Publication Date Title
HU230189B1 (hu) Szerotonin újrafelvételt gátló fenilpiperazin-származékok
Chinthala et al. Synthesis, docking and ADMET studies of novel chalcone triazoles for anti-cancer and anti-diabetic activity
CN106163516B (zh) 异吲哚啉组合物和治疗神经变性疾病的方法
RU2213743C2 (ru) Производное тиенилазолилалкоксиэтанамина, способ его получения (варианты), фармацевтическая композиция, промежуточный продукт и способ его получения (варианты)
JPS6089474A (ja) モルフイナン誘導体，その製造方法，及び該化合物を含有する抗腫瘍剤
NZ200526A (en) 1,2,3,4-tetrahydro-2-naphthylamine derivatives
US6355642B1 (en) Tetrahydrobenzindole compounds
JPH0710853B2 (ja) チアジン（又はオキサジン）誘導体、その製法及びその合成中間体
JPH05509311A (ja) １，４―二置換ピペラジン
CZ279282B6 (cs) Způsob přípravy 1-/(diarylmethoxy)- alkyl/ pyrrolidinů a piperidinů
JP2012523416A (ja) セロトニンおよびノルエピネフリン再取り込み阻害剤
US4395559A (en) 2,3-Indoledione derivatives
FI108862B (fi) 4(p-fluorifenyyli)-3-[[3,4-(metyleenidioksi)fenoksi]metyyli]-piperidiinin N-p-halogeenibentsoyylimetyylijohdannaiset
FR2662442A1 (fr) Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.
JP5486008B2 (ja) １‐ブチル‐２‐ヒドロキシアラルキルピペラジン誘導体およびその抗鬱剤としての使用
US4845096A (en) Benzofuran derivatives and antiulcerogenic agents containing same
CA2727669A1 (fr) Nouveaux derives de (piperazinyl ponte)-1-alcanone et leur utilisation comme inhibiteurs de p75
JPS59101475A (ja) 新規ピペラジン誘導体およびその製造法ならびにこれを含有する脳循環改善剤
JP4769726B2 (ja) コンセントリコリド及びその誘導体、それらを調製する工程、それを含む薬学的組成物並びにその使用
FR2753970A1 (fr) Derives de n-(benzothiazol-2-yl) piperidine-1-ethanamine, leur preparation et leur application en therapeutique
KR20000018305A (ko) Cdk 저해제로서 유용한 크로멘 유도체
WO2005094896A2 (en) Targeted serotonin reuptake inhibitors
HU196797B (en) Process for producing 5-substituted oktahydro-indoline derivatives
AU615907B2 (en) Benzofuro (3,2-c) quinoline compounds
TW483893B (en) S-(+)-3-{1(1,3-benzodioxol-5-yl)-2-[(2-methoxy-4-methylphenyl)sulfonylamino]-2-oxoethyl}-1-methyl-1H-indole-6-carboxylic acid, a process for preparing the same, and a pharmaceutical composition containing thereof